Anti-tumor Immunotherapy via Antigen Delivery from a Live Attenuated Genetically Engineered Pseudomonas aeruginosa Type III Secretion System-Based Vector

Molecular Therapy

Volumn 14, Issue 5, 2006, Pages 656-661

  Epaulard, Olivier ^a   Toussaint, Bertrand ^a   Quenee, Lauriane ^a   Derouazi, Madiha ^a   Bosco, Nabil ^b   Villiers, Christian ^b   Le Berre, Rozenn ^c   Guery, Benoit ^c   Filopon, Didier ^a   Crombez, Laurence ^a,d   Marche, Patrice N ^b   Polack, Benoit ^a  

^a UNIV GRENOBLE ALPES   (France)

^b CEA GRENOBLE   (France)

^c UNIV LILLE   (France)

^d Protein'eXpert SA   (France)

Author keywords

cancer; dendritic cell; immunotherapy; Pseudomonas aeruginosa; type III secretion system; vaccine

Indexed keywords

CANCER VACCINE; OVALBUMIN; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE DELIVERY SYSTEM; GENE TRANSFER; GENE TRANSLOCATION; GENE VECTOR; GENETIC ENGINEERING; HOST CELL; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MAMMAL CELL; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PLASMID; PSEUDOMONAS AERUGINOSA; THORAX TUMOR; WESTERN BLOTTING;

ANIMALS; ANTIGENS; CELLS, CULTURED; DENDRITIC CELLS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; IMMUNOTHERAPY; MICE; NEOPLASMS; PSEUDOMONAS AERUGINOSA;

ANIMALIA; BACTERIA (MICROORGANISMS); MAMMALIA; PSEUDOMONAS AERUGINOSA;

EID: 33749248510     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.06.011     Document Type: Article

References (22)

1. Berzofsky J.A., et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113 (2004) 1515-1525
2. Chabalgoity J.A., Dougan G., Mastroeni P., and Aspinall R.J. Live bacteria as the basis for immunotherapies against cancer. Expert Rev. Vaccines 1 (2002) 495-505
3. Radford K.J., et al. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther. 9 (2002) 1455-1463
4. Russmann H., Shams H., Poblete F., Fu Y., Galan J.E., and Donis R.O. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281 (1998) 565-568
5. Polack B., Vergnaud S., Paclet M.H., Lamotte D., Toussaint B., and Morel F. Protein delivery by Pseudomonas type III secretion system: ex vivo complementation of p67(phox)-deficient chronic granulomatous disease. Biochem. Biophys. Res. Commun. 275 (2000) 854-858
6. Sory M.P., Boland A., Lambermont I., and Cornelis G.R. Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the cyaA gene fusion approach. Proc. Natl. Acad. Sci. USA 92 (1995) 11998-12002
7. Hueck C.J. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol. Mol. Biol. Rev. 62 (1998) 379-433
8. Dacheux D., Goure J., Chabert J., Usson Y., and Attree I. Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages. Mol. Microbiol. 40 (2001) 76-85
9. Wang H.Y., et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest. 109 (2002) 1463-1470
10. + T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice. Surgery 133 (2003) 404-410
11. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10 (2004) 475-480
12. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
13. Nemunaitis J., et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10 (2003) 737-744
14. Toso J.F., et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20 (2002) 142-152
15. Dacheux D., Attree I., Schneider C., and Toussaint B. Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system. Infect. Immun. 67 (1999) 6164-6167
16. Quenee L., Lamotte D., and Polack B. Combined sacB-based negative selection and Cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa. Biotechniques 38 (2005) 63-67
17. Scholz O., Thiel A., Hillen W., and Niederweis M. Quantitative analysis of gene expression with an improved green fluorescent protein. Eur. J. Biochem. 267 (2000) 1565-1570
18. Stark M.J. Multicopy expression vectors carrying the lac repressor gene for regulated high-level expression of genes in Escherichia coli. Gene 51 (1987) 255-267
19. Tucker K.A., Lilly M.B., Heck Jr. L., and Rado T.A. Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. Blood 70 (1987) 372-378
20. Berthier R., Martinon-Ego C., Laharie A.M., and Marche P.N. A two-step culture method starting with early growth factors permits enhanced production of functional dendritic cells from murine splenocytes. J. Immunol. Methods 239 (2000) 95-107
21. Karttunen J., Sanderson S., and Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. USA 89 (1992) 6020-6024
22. Brown D.M., Fisher T.L., Wei C., Frelinger J.G., and Lord E.M. Tumours can act as adjuvants for humoral immunity. Immunology 102 (2001) 486-497